knowledge -WSS

knowledge

author：hotspot 2025-10-02 22:56:40 - browse：52

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Medicare proposal to cover medical devices draws a mixed reaction

leisure time

focus

WSS

The biotech scorecard for Q1: 17 stock

Feng Zhang CRISPR delivery startup lays off quarter of staff

Supreme Court strikes down use of affirmative action

The biotech scorecard for Q1: 17 stock

3 medical device trends to watch in 2024

UCB departs biotech trade group BIO

leisure time

knowledge

leisure time

How to save PrEP access — and even expand it

Novavax promises a turnaround & Lilly roils the obesity market

New air purifier tech could be key to improving indoor air quality

Goldman Sachs launches $650M fund for life science investments

The high cost of giving birth even with insurance

Ahead of JPM, here's who's profiting most in health care

Anesthesiologist group: stop taking Ozempic before surgery

Drug repurposing or repositioning? The language matters

Cancer drug shortages should be causing more outrage

Bright Health sells Medicare Advantage business to Molina

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In Memoriam: Notable people who died in 2023

Feng Zhang, Grail founder join forces on new gene editing startup

Peter Hotez and the public health issue of online harassment

Bright Health sells Medicare Advantage business to Molina

Cancer drug shortages should be causing more outrage

focus

leisure time

focus

focus